Natural history of neuromodulation devices and therapies: a patient-centered survival analysis.

J Neurosurg 2019 Apr 19:1-7. Epub 2019 Apr 19.

OBJECTIVEDespite rapid development and expansion of neuromodulation technologies, knowledge about device and/or therapy durability remains limited. The aim of this study was to evaluate the long-term rate of hardware and therapeutic failure of implanted devices for several neuromodulation therapies.METHODSThe authors performed a retrospective analysis of patients' device and therapy survival data (Kaplan-Meier survival analysis) for deep brain stimulation (DBS), vagus nerve stimulation (VNS), and spinal cord stimulation (SCS) at a single institution (years 1994-2015).RESULTSDuring the study period, 450 patients underwent DBS, 383 VNS, and 128 SCS. For DBS, the 5- and 10-year initial device survival was 87% and 73%, respectively, and therapy survival was 96% and 91%, respectively. For VNS, the 5- and 10-year initial device survival was 90% and 70%, respectively, and therapy survival was 99% and 97%, respectively. For SCS, the 5- and 10-year initial device survival was 50% and 34%, respectively, and therapy survival was 74% and 56%, respectively. The average initial device survival for DBS, VNS, and SCS was 14 years, 14 years, and 8 years while mean therapy survival was 18 years, 18 years, and 12.5 years, respectively.CONCLUSIONSThe authors report, for the first time, comparative device and therapy survival rates out to 15 years for large cohorts of DBS, VNS, and SCS patients. Their results demonstrate higher device and therapy survival rates for DBS and VNS than for SCS. Hardware failures were more common among SCS patients, which may have played a role in the discontinuation of therapy. Higher therapy survival than device survival across all modalities indicates continued therapeutic benefit beyond initial device failures, which is important to emphasize when counseling patients.

Download full-text PDF

Source
https://thejns.org/view/journals/j-neurosurg/aop/article-10.
Publisher Site
http://dx.doi.org/10.3171/2019.2.JNS182450DOI Listing

Still can't find the full text of the article?

We can help you send a request to the authors directly.
April 2019
10 Reads

Article Mentions


Provided by Crossref Event Data
twitter
Twitter:
April 25, 2019, 1:45 am EST
twitter
Twitter:
April 24, 2019, 8:46 pm EST
twitter
Twitter:
April 24, 2019, 1:44 pm EST
twitter
Twitter:
April 24, 2019, 12:37 pm EST
twitter
Twitter:
April 24, 2019, 12:32 pm EST
twitter
Twitter:
April 24, 2019, 11:11 am EST
twitter
Twitter:
April 24, 2019, 10:00 am EST
twitter
Twitter:
April 24, 2019, 9:30 am EST
twitter
Twitter:
April 22, 2019, 1:29 am EST
twitter
Twitter:
April 22, 2019, 12:07 am EST
twitter
Twitter:
April 21, 2019, 4:01 pm EST
twitter
Twitter:
April 21, 2019, 2:48 pm EST
twitter
Twitter:
April 21, 2019, 1:25 pm EST
twitter
Twitter:
April 21, 2019, 1:19 pm EST
twitter
Twitter:
April 21, 2019, 1:12 am EST

Publication Analysis

Top Keywords

therapy survival
32
device survival
20
initial device
20
survival
15
vns scs
12
device therapy
12
years years
12
dbs vns
12
10-year initial
12
therapy
10
device
10
survival analysis
8
scs patients
8
years
8
survival rates
8
scs
7
dbs
6
vns
6
initial
5
450 patients
4

References

(Supplied by CrossRef)

Similar Publications